PRESS RELEASE published on 01/02/2026 at 08:00, 7 months 2 days ago CEO transition at Neovii Pharmaceuticals: Frédéric Prince to succeed Christian Loss, effective January 1st, 2026 Frédéric Prince to succeed Christian Loss as CEO of Neovii Pharmaceuticals on January 1st, 2026. Dr. Loss retires after distinguished career. Dr. Prince brings extensive experience in research & development and commercial functions CEO Transition Leadership Roles Neovii Pharmaceuticals Frédéric Prince Christian Loss
BRIEF published on 12/24/2025 at 13:03, 7 months 11 days ago DiNABIOS Welcomes FDA Modernization Act 3.0 Passage Innovation Drug Development FDA Modernization DiNABIOS New Approach Methodologies
BRIEF published on 12/24/2025 at 13:03, 7 months 11 days ago DiNABIOS se félicite de l'adoption de la loi de modernisation de la FDA 3.0 Innovation Développement De Médicaments DiNABIOS Modernisation De La FDA Nouvelles Méthodologies D'approche
PRESS RELEASE published on 12/24/2025 at 12:58, 7 months 11 days ago DiNABIOS Applauds Historic U.S. Senate Passage of FDA Modernization Act 3.0, Advancing Human‑Relevant New Approach Methodologies (NAMs) DiNABIOS celebrates U.S. Senate passage of FDA Modernization Act 3.0, promoting human-relevant NAMs for drug development and reducing animal testing Drug Development DiNABIOS FDA Modernization Act 3.0 NAMs Animal Testing
BRIEF published on 12/23/2025 at 14:41, 7 months 12 days ago DiNAQOR présente une plateforme révolutionnaire pour l'administration de médicaments de précision. Biotechnologie Thérapie Génique Médecine De Précision DiNAQOR Perfusion Loco-régionale
BRIEF published on 12/23/2025 at 14:41, 7 months 12 days ago DiNAQOR Introduces Breakthrough Platform for Precision Drug Delivery Biotechnology Precision Medicine Gene Therapy DiNAQOR Loco-Regional Perfusion
PRESS RELEASE published on 12/23/2025 at 14:36, 7 months 12 days ago DiNAQOR and Academic Partners Launch Paradigm Shift in In Vivo Delivery of Advanced Therapies DiNAQOR and academic partners introduce groundbreaking percutaneous platform for organ-specific delivery of advanced therapies, addressing critical challenges in gene and cell therapy development Advanced Therapies DiNAQOR Academic Partners Percutaneous Platform Organ-specific Delivery
BRIEF published on 12/22/2025 at 14:55, 7 months 13 days ago DiNAQOR renforce son équipe dirigeante grâce à des nominations stratégiques clés Biotechnologie Changements De Direction Nominations Stratégiques DiNAQOR AG Dr Christian Thirion
BRIEF published on 12/22/2025 at 14:55, 7 months 13 days ago DiNAQOR Bolsters Leadership with Key Strategic Appointments Biotechnology Leadership Changes Strategic Appointments Dr. Christian Thirion DiNAQOR AG
PRESS RELEASE published on 12/22/2025 at 14:50, 7 months 13 days ago DiNAQOR Strengthens Group Leadership with Strategic Appointments DiNAQOR strengthens group leadership by appointing Dr. Christian Thirion as CEO of DiNATEQ AG and Dr. Josef El Andari as Chief Scientific Officer, reinforcing its focus on next-generation life science ventures Biotechnology Life Science Strategic Appointments DiNAQOR Group Leadership
Published on 08/04/2026 at 22:30, 54 minutes ago Nextech3D.ai Provides Update on Acquisition of Remaining ARway Shares
Published on 08/04/2026 at 17:00, 6 hours 24 minutes ago Moderna annonce le début d'un essai clinique de phase 1 portant sur l’ARNm-1469, son vaccin expérimental contre l'ébolavirus de Bundibugyo
Published on 08/04/2026 at 16:25, 6 hours 59 minutes ago ACCESS Newswire to Host Second Quarter Earnings Conference Call on August 11, 2026
Published on 08/04/2026 at 15:00, 8 hours 24 minutes ago Infield Minerals Expands Land Position at the Kings Canyon Gold Project in Utah
Published on 08/04/2026 at 22:03, 1 hour 20 minutes ago #FutureFresenius: Excellent Q2 performance demonstrates structural step-up – Guidance raised
Published on 08/04/2026 at 22:01, 1 hour 22 minutes ago EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius raises its earnings guidance for fiscal year 2026 due to strong operational business performance
Published on 08/04/2026 at 20:05, 3 hours 18 minutes ago Hard Rock Cafe and Coca-Cola® Launch Hard Rock Rising Music Competition for Emerging Artists
Published on 08/04/2026 at 19:39, 3 hours 44 minutes ago EQS-Adhoc: Basler AG financial results for the first 6 months of 2026: Strong business performance in the first half of the year; company raises its 2026 forecast once again
Published on 08/04/2026 at 18:32, 4 hours 51 minutes ago Capital et droits de vote au 31 juillet 2026
Published on 08/04/2026 at 18:32, 4 hours 51 minutes ago Total number of voting rights and shares making up the share capital at July 31, 2026
Published on 08/04/2026 at 17:45, 5 hours 39 minutes ago INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL